SC-N132, Feasibility of Ex Vivo Drug Sensitivity and Genomic Screening for Pediatric Patients with Relapsed and Refractory Acute Leukemias
SC-N132
What is the goal of the study?
The primary objective is to determine the feasibility of identifying patient specific therapeutic regimens based on the pairing of ex vivo drug sensitivity testing and genomic sequencing in pediatric patients with relapsed/refractory leukemias within 45 days.
Who can participate in the study?
Please contact the study team listed below to learn more.